Randomized Trialmoderate evidence
Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.
Nature medicine·August 19, 2026·PMID 42618633
Why it mattersCardiomyocyte replacement is a potential regenerative strategy for advanced heart failure, but arrhythmic risk is a major concern. This early trial provides the first randomized safety data on allogeneic iPSC-derived cardiomyocytes in humans, showing both promising functional improvements and a predictable, transient arrhythmic burden that must be weighed in future studies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled